A Case of Ornithine Transcarbamylase Deficiency in 11-month-old Female who Presented Periodic Vomiting and Intermittent Consciousness Change |
Kim, Jin Ah
(Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Kim, Jin Sup (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) Huh, Rimm (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) Cho, Sung Yoon (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) Jin, Dong Kyu (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) |
1 | Caldovic L, Abdikarim I, Narain S, Tuchman M, Morizono H. Genotype-Phenotype Correlations in Ornithine Transcarbamylase Deficiency: A Mutation Update. J Genet Genomics 2015;42:181-94. DOI |
2 | Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv Pediatr 1996; 43:127-70. |
3 | Hudak ML, Jones MD, Jr., Brusilow SW. Differentiation of transient hyperammonemia of the newborn and urea cycle enzyme defects by clinical presentation. J Pediatr 1985;107:712-9. DOI |
4 | Choi JH, Lee BH, Kim JH, Kim GH, Kim YM, Cho J, et al. Clinical outcomes and the mutation spectrum of the OTC gene in patients with ornithine transcarbamylase deficiency. J Hum Genet 2015. |
5 | McCullough BA, Yudkoff M, Batshaw ML, Wilson JM, Raper SE, Tuchman M. Genotype spectrum of ornithine transcarbamylase deficiency: correlation with the clinical and biochemical phenotype. Am J Med Genet 2000;93:313-9. DOI |
6 | Helman G, Pacheco-Colon I, Gropman AL. The urea cycle disorders. Semin Neurol 2014;34:341-9. DOI |
7 | Gropman AL, Batshaw ML. Cognitive outcome in urea cycle disorders. Mol Genet Metab 2004;81 Suppl 1: S58-62. |
8 | Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. Ornithine transcarbamylase deficiency. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al., editors. GeneReviews(R). Seattle (WA): University of Washington, Seattle, 1993:1993-2015. |
9 | Brown CJ. Skewed X-Chromosome Inactivation: Cause or Consequence? Journal of the National Cancer Institute 1999;91:304-5. DOI |
10 | Seminara J, Tuchman M, Krivitzky L, Krischer J, Lee HS, Lemons C, et al. Establishing a consortium for the study of rare diseases: The Urea Cycle Disorders Consortium. Mol Genet Metab 2010;100 Suppl 1: S97-105. DOI |
11 | Glasgow J, Middleton B. Reye syndrome-insights on causation and. Arch Dis Child 2001;85:351-3. DOI |
12 | Maestri NE, Brusilow SW, Clissold DB, Bassett SS. Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med 1996;335:855-9. DOI |
13 | Monneret C. Histone deacetylase inhibitors. Eur J Med Chem 2005;40:1-13. DOI |
14 | Urea Cycle Disorders Conference Group. Consensus statement from a conference for the management of patients with urea cycle disorders. J Pediatr 2001;138: S1-5. DOI |
15 | Caldovic L, Abdikarim I, Narain S, Tuchman M, Morizono H. Genotype-Phenotype Correlations in Ornithine Transcarbamylase Deficiency: A Mutation Update. JGG 2015;42:181-94. |